Variable | Community (n = 81) | Hospital (n = 33) | Total (n = 114) | p-values |
---|---|---|---|---|
Age, median (IQR) | 65 (51.5–77.5) | 64 (50–74) | 64 (50.8–75) | 0.334 |
Baseline dry weight (kg), median (IQR) | 71.0 (60.5–85.5) | 72.0 (61.0–92.3) | 72.0 (60.9–87.1) | 0.413 |
Male (%) | 46 (56.8) | 20 (60.6) | 68 (59.7) | 0.894 |
Ethnicity (%) | 0.039* | |||
 Caucasian | 55 (67.9) | 30 (90.9) | 85 (74.6) | |
 Asian | 13 (16.1) | 1 (3.0) | 14 (12.3) | |
 Other | 13 (16.1) | 2 (6.1) | 15 (13.2) | |
Primary indication of ESRD requiring HD (%) | 0.922 | |||
 Diabetes | 34 (42.0) | 12 (36.4) | 46 (40.4) | |
 Glomerulonephritis | 13 (16.1) | 6 (18.2) | 19 (16.7) | |
 Hypertension | 7 (8.6) | 2 (6.1) | 9 (7.9) | |
 Polycystic kidney disease | 4 (4.9) | 2 (6.1) | 6 (5.3) | |
 Other | 18 (22.2) | 10 (30.3) | 28 (24.6) | |
 Unknown | 5 (6.2) | 1 (3.0) | 6 (5.3) | |
Vascular access type at enrollment (%) | 0.018* | |||
 AV fistula | 62 (76.5) | 19 (57.6) | 81 (71.1) | |
 AV graft | 10 (12.4) | 3 (9.1) | 13 (11.4) | |
 Catheter | 9 (11.1) | 11 (33.3) | 20 (17.5) | |
Years receiving HD at enrollment, median (IQR) | 3.17 (1.1–5.9) | 1.5 (0.4–3.5) | 2.4 (0.9–5.5) | 0.005* |
Current smokers (%) | 11 (13.6) | 4 (12.1) | 15 (13.2) | 1.000 |
Comorbidities | ||||
 Diabetes | 43 (53.1) | 12 (36.4) | 55 (48.2) | 0.105 |
 Cardiovascular disease | 78 (96.3) | 30 (90.1) | 108 (94.7) | 0.354 |
 Dyslipidaemia | 32 (39.5) | 15 (45.5) | 47 (41.2) | 0.558 |
 Respiratory disease | 10 (12.3) | 11 (33.3) | 21 (18.4) | 0.009* |
 Previous or current diagnosis of cancer | 14 (17.3) | 8 (24.2) | 22 (19.3) | 0.393 |
Allergy to antibiotics (%) | 1.000 | |||
Allergy to one antibiotic only: | ||||
 Pencillins | 5 (6.2) | 2 (6.1) | 7 (6.1) | |
 Cephalosporins | 2 (2.5) | 1 (3.0) | 3 (2.6) | |
 Other antibiotics | 2 (2.5) | 1 (3.0) | 3 (2.6) | |
 Allergies to two or more antibiotics | 6 (7.4) | 2 (6.1) | 8 (7.0) | |
Previous kidney transplant (%) | 11 (13.6) | 9 (27.3) | 20 (17.5%) | 0.081 |
Anuric (%) | 46 (56.8) | 16 (48.5) | 62 (54.4) | 0.298 |